Meet the Andarta team.
Meet the Andarta team
Andarta Therapeutics is led by a team with deep expertise in neuroscience, drug discovery, and company building, united by a shared commitment to developing transformative therapies for neurodegenerative disease.
Meet the Andarta team.
Andarta Therapeutics is led by a team with deep expertise in neuroscience, drug discovery, and company building, united by a shared commitment to developing transformative therapies for neurodegenerative disease.
Ian Reynolds, PhD
Chief Executive Officer & Co-Founder
Ian Reynolds is a neuropharmacologist with extensive experience in central nervous system drug discovery and development, including senior roles at Merck and Teva. He is a current and former scientific advisor to leading Parkinson’s organizations, including the Michael J. Fox Foundation, the Parkinson’s Foundation, and ASAP.
Previously, Dr. Reynolds served as Professor of Pharmacology at the University of Pittsburgh, where his research focused on neurodegeneration, Parkinson’s disease, and mitochondrial dysfunction. His career bridges academic discovery and pharmaceutical development, providing strong leadership for translational neuroscience programs.
Ian Reynolds, PhD
Chief Executive Officer & Co-Founder
Ian Reynolds is a neuropharmacologist with extensive experience in central nervous system drug discovery and development, including senior roles at Merck and Teva. He is a current and former scientific advisor to leading Parkinson’s organizations, including the Michael J. Fox Foundation, the Parkinson’s Foundation, and ASAP.
Previously, Dr. Reynolds served as Professor of Pharmacology at the University of Pittsburgh, where his research focused on neurodegeneration, Parkinson’s disease, and mitochondrial dysfunction. His career bridges academic discovery and pharmaceutical development, providing strong leadership for translational neuroscience programs.
Ian Reynolds, PhD
Chief Executive Officer & Co-Founder
Ian Reynolds is a neuropharmacologist with extensive experience in central nervous system drug discovery and development, including senior roles at Merck and Teva. He is a current and former scientific advisor to leading Parkinson’s organizations, including the Michael J. Fox Foundation, the Parkinson’s Foundation, and ASAP.
Previously, Dr. Reynolds served as Professor of Pharmacology at the University of Pittsburgh, where his research focused on neurodegeneration, Parkinson’s disease, and mitochondrial dysfunction. His career bridges academic discovery and pharmaceutical development, providing strong leadership for translational neuroscience programs.
Janette Dixon, DBA
Chief Business Officer & Co-Founder
Janette Dixon brings more than 25 years of experience across pharma and biotech, including roles as a chief executive and as a management consultant. She is a serial biotech entrepreneur with a proven track record of building companies, assembling high-performing teams, and guiding early-stage ventures through critical growth phases.
Her extensive business experience includes strategic advisory work and deal-making for academic institutions and biotechnology companies, supporting partnerships, licensing, and company formation.
Janette Dixon, DBA
Chief Business Officer & Co-Founder
Janette Dixon brings more than 25 years of experience across pharma and biotech, including roles as a chief executive and as a management consultant. She is a serial biotech entrepreneur with a proven track record of building companies, assembling high-performing teams, and guiding early-stage ventures through critical growth phases.
Her extensive business experience includes strategic advisory work and deal-making for academic institutions and biotechnology companies, supporting partnerships, licensing, and company formation.
Janette Dixon, DBA
Chief Business Officer & Co-Founder
Janette Dixon brings more than 25 years of experience across pharma and biotech, including roles as a chief executive and as a management consultant. She is a serial biotech entrepreneur with a proven track record of building companies, assembling high-performing teams, and guiding early-stage ventures through critical growth phases.
Her extensive business experience includes strategic advisory work and deal-making for academic institutions and biotechnology companies, supporting partnerships, licensing, and company formation.
Richard Wade-Martins, PhD
Co-Founder & Scientific Advisor
Richard Wade-Martins is Professor of Molecular Neuroscience and Director of the Oxford Parkinson’s Disease Centre at the University of Oxford. He is an internationally recognized leader in Parkinson’s disease and neurodegeneration research.
Professor Wade-Martins has an extensive record of academic-industry collaboration and translational drug discovery, helping to bridge fundamental biology and therapeutic development. His scientific leadership provides critical guidance for Andarta’s disease-focused strategy.
Richard Wade-Martins, PhD
Co-Founder & Scientific Advisor
Richard Wade-Martins is Professor of Molecular Neuroscience and Director of the Oxford Parkinson’s Disease Centre at the University of Oxford. He is an internationally recognized leader in Parkinson’s disease and neurodegeneration research.
Professor Wade-Martins has an extensive record of academic-industry collaboration and translational drug discovery, helping to bridge fundamental biology and therapeutic development. His scientific leadership provides critical guidance for Andarta’s disease-focused strategy.
Richard Wade-Martins, PhD
Co-Founder & Scientific Advisor
Richard Wade-Martins is Professor of Molecular Neuroscience and Director of the Oxford Parkinson’s Disease Centre at the University of Oxford. He is an internationally recognized leader in Parkinson’s disease and neurodegeneration research.
Professor Wade-Martins has an extensive record of academic-industry collaboration and translational drug discovery, helping to bridge fundamental biology and therapeutic development. His scientific leadership provides critical guidance for Andarta’s disease-focused strategy.